SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+3.25%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.56B
AUM Growth
+$1.56B
(-5.2%)
Cap. Flow
-$70.3M
Cap. Flow
% of AUM
-4.51%
Top 10 Holdings %
Top 10 Hldgs %
66.12%
Holding
83
New
13
Increased
14
Reduced
20
Closed
13
Top Buys
| 1 |
AbbVie
ABBV
|
$29.4M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$18.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$17.3M |
| 4 |
Zoetis
ZTS
|
$14.8M |
| 5 |
Zymeworks
ZYME
|
$11.9M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$33.4M |
| 2 |
Biogen
BIIB
|
$21.9M |
| 3 |
Neurocrine Biosciences
NBIX
|
$19.8M |
| 4 |
Insulet
PODD
|
$19.2M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$17.8M |
Sector Composition
| 1 | Healthcare | 98.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $346M | 20.48% | 3,102,960 +2,400 | +0.1% | +$267K |
|
|
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $239M | 14.15% | 1,953,077 +636 | +0% | +$77.8K |
|
3
Ascendis Pharma
ASND
$11.8B
| $79.7M | 4.72% | 499,824 -22,099 | -4% | -$3.52M |
|
|
JBIO
4
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $78.9M | 4.67% | 3,758,686 | – | – |
|
5
AstraZeneca
AZN
$248B
| $67.8M | 4.01% | 1,128,272 +168,640 | +18% | +$10.1M |
|
6
Y-mAbs Therapeutics
YMAB
$388M
| $62.6M | 3.71% | 2,194,278 | – | – |
|
7
Vera Therapeutics
VERA
$1.38B
| $50.6M | 2.99% | 2,914,776 | – | – |
|
8
United Therapeutics
UTHR
$13.8B
| $41M | 2.43% | 222,094 +6,009 | +3% | +$1.11M |
|
9
Bolt Biotherapeutics
BOLT
$9.85M
| $34.8M | 2.06% | 2,754,437 | – | – |
|
10
Align Technology
ALGN
$10.3B
| $31.3M | 1.85% | 47,000 -93 | -0.2% | -$61.9K |
|
|
11
AbbVie
ABBV
$372B
| $29.4M | 1.74% | +272,600 | New | +$29.4M |
|
|
GRTX
12
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $25M | 1.48% | 3,083,712 | – | – |
|
13
Heron Therapeutics
HRTX
$207M
| $24.6M | 1.46% | 2,301,179 +833,504 | +57% | +$8.91M |
|
|
INZY
14
DELISTED
Inozyme Pharma
INZY
| $23.5M | 1.39% | 2,028,308 | – | – |
|
15
DexCom
DXCM
$29.5B
| $20.4M | 1.21% | 37,266 +3,553 | +11% | +$1.94M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $18.7M | 1.11% | +181,860 | New | +$18.7M |
|
17
NextCure
NXTC
$13.5M
| $18M | 1.07% | 2,671,856 | – | – |
|
|
AKUS
18
DELISTED
Akouos, Inc. Common Stock
AKUS
| $17.6M | 1.04% | 1,515,074 | – | – |
|
|
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $17.3M | 1.02% | +157,487 | New | +$17.3M |
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15.8M | 0.94% | 157,488 +77,887 | +98% | +$7.84M |
|
21
Cytokinetics
CYTK
$4.23B
| $15.2M | 0.9% | 426,632 -54,691 | -11% | -$1.95M |
|
|
OBSV
22
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $14.8M | 0.87% | 4,749,623 | – | – |
|
|
23
Zoetis
ZTS
$69.3B
| $14.8M | 0.87% | +76,000 | New | +$14.8M |
|
24
Insmed
INSM
$28.8B
| $14.7M | 0.87% | 535,120 -309,049 | -37% | -$8.51M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $14.5M | 0.86% | 157,279 -141,221 | -47% | -$13.1M |
|